Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback